BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non-small cell lung cancer

KRAS mutation is present in approximately 30% of human lung adenocarcinomas. Although recent advances in targeted therapy have shown great promise, effective targeting of KRAS remains elusive, and concurrent alterations in tumor suppressors render KRAS-mutant tumors even more resistant to existing t...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancer Immunol Res
Κύριοι συγγραφείς: Adeegbe, Dennis O., Liu, Shengwu, Hattersley, Maureen M., Bowden, Michaela, Zhou, Chensheng W., Li, Shuai, Vlahos, Raven, Grondine, Michael, Dolgalev, Igor, Ivanova, Elena V., Quinn, Max M., Gao, Peng, Hammerman, Peter S., Bradner, James E., Diehl, J. Alan, Rustgi, Anil K., Bass, Adam J., Tsirigos, Aristotelis, Freeman, Gordon J., Chen, Huawei, Wong, Kwok-Kin
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2018
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6170698/
https://ncbi.nlm.nih.gov/pubmed/30087114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-18-0077
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια